Amylin Pharmaceuticals (AMLN -46%) and Alkermes (ALKS -27.3%) are the day's biggest losers, as...

|By:, SA News Editor

Amylin Pharmaceuticals (AMLN -46%) and Alkermes (ALKS -27.3%) are the day's biggest losers, as shares were crushed after the FDA declined to approve their diabetes drug Bydureon. On the flip side, the news was a boon to shares of Novo Nordisk (NVO +10.3%), which markets a rival medication that received FDA approval in January.